Last reviewed · How we verify
Fluticasone Furoate/GW642444
Fluticasone Furoate/GW642444 is a Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
Fluticasone furoate is a long-acting inhaled corticosteroid that reduces airway inflammation, while GW642444 is a long-acting beta-2 agonist that relaxes airway smooth muscle.
Fluticasone furoate is a long-acting inhaled corticosteroid that reduces airway inflammation, while GW642444 is a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Fluticasone Furoate/GW642444 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (GW642444/vilanterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
This combination therapy works synergistically: fluticasone furoate binds glucocorticoid receptors to suppress inflammatory mediators and immune cell activation in the airways, while GW642444 (vilanterol) activates beta-2 adrenergic receptors to promote bronchial smooth muscle relaxation and bronchodilation. Together they provide both anti-inflammatory and bronchodilatory effects for sustained airway control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Furoate/GW642444 CI brief — competitive landscape report
- Fluticasone Furoate/GW642444 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Fluticasone Furoate/GW642444
What is Fluticasone Furoate/GW642444?
How does Fluticasone Furoate/GW642444 work?
What is Fluticasone Furoate/GW642444 used for?
Who makes Fluticasone Furoate/GW642444?
What drug class is Fluticasone Furoate/GW642444 in?
What development phase is Fluticasone Furoate/GW642444 in?
What are the side effects of Fluticasone Furoate/GW642444?
What does Fluticasone Furoate/GW642444 target?
Related
- Drug class: All Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination drugs
- Target: All drugs targeting Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (GW642444/vilanterol)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Compare: Fluticasone Furoate/GW642444 vs similar drugs
- Pricing: Fluticasone Furoate/GW642444 cost, discount & access